Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 6065 word(s) 6065 2021-06-28 05:32:34 |
2 format correct -21 word(s) 6044 2021-07-12 10:22:13 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Guiot, J. Radiomics in Lung Diseases Imaging. Encyclopedia. Available online: (accessed on 13 June 2024).
Guiot J. Radiomics in Lung Diseases Imaging. Encyclopedia. Available at: Accessed June 13, 2024.
Guiot, Julien. "Radiomics in Lung Diseases Imaging" Encyclopedia, (accessed June 13, 2024).
Guiot, J. (2021, July 12). Radiomics in Lung Diseases Imaging. In Encyclopedia.
Guiot, Julien. "Radiomics in Lung Diseases Imaging." Encyclopedia. Web. 12 July, 2021.
Radiomics in Lung Diseases Imaging

Artificial intelligence (AI) has increasingly been serving the field of radiology over the last 50 years. As modern medicine is evolving towards precision medicine, offering personalized patient care and treatment, the requirement for robust imaging biomarkers has gradually increased. Radiomics, a specific method generating high-throughput extraction of a tremendous amount of quantitative imaging data using data-characterization algorithms, has shown great potential in individuating imaging biomarkers. Radiomic analysis can be implemented through the following two methods: hand-crafted radiomic features extraction or deep learning algorithm. Its application in lung diseases can be used in clinical decision support systems, regarding its ability to develop descriptive and predictive models in many respiratory pathologies.

radiomics artificial intelligence lung diseases precision medicine

1. Introduction

Described as the “high-throughput extraction of large amounts of image features from radiographic images” [1], radiomics is the subject of much research. This quantitative instrument is beginning to establish itself as a recognized imaging biomarker and paraclinical tool, serving both the fields of diagnosis and prognosis, along with predicting or monitoring response to treatment. The aim of radiomics is to extract quantitative, actionable information from standard-of-care medical images (computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), etc.), which are not easily visible or quantifiable with the naked eye, in order to build a model assessing clinical outcomes, including diagnostic, prognostic or predictive perspectives, to precisely identify and describe a pathological entity.
The following two methods can be used to perform a radiomic analysis: hand-crafted feature processing, or deep learning (DL). Hand-crafted feature (e.g., texture, shape, intensity, wavelet) processing will afford information on a specific targeted area of the imaging modality, distinctively from other related data (e.g., clinical, biological, genomic, histological, or treatment-related data). Contrastingly, deep learning methods will proceed to an extensive data-driven approach, processing a huge amount of information on the model of a simplified neural brain network, and without needing prior image segmentation (Figure 1).
Figure 1. Traditional radiomics and deep learning approaches. Radiomic analysis workflow for handcrafted features (top) and deep learning method (bottom).
The basic concepts inherent to radiomics and artificial intelligence are displayed in Table 1. Some of these concepts will be repeatedly used in the following sections.
Table 1. AI and radiomics: basic concepts.
Terminology Used in Radiomics and AI
Artificial intelligence Wide-ranging branch of computer science, generating complex software that perform tasks that would typically have required human intelligence, by sensing and responding to a feature of their environment.
CAD (Computer Aided Detection or Diagnosis) Technology combining elements of artificial intelligence with radiological and pathology image processing. Its aim is to assist in the detection and/or diagnosis of diseases, improving the accuracy of radiologists with a reduction in time in the interpretation of images.
Radiomics Method that extracts a large number of quantitative features from radiographic medical images using data-characterization algorithms, to help in disease diagnosis and prognosis.
Machine Learning Field in artificial intelligence studying computer algorithms that improve automatically through experience, by building a model based on sample data, known as “training data”, in order to make predictions or decisions.
Supervised learning: The computer receives example inputs and their foreseen outputs. Its goal is to learn a general and reproducible function that links inputs to outputs.
Unsupervised learning: The computer receives no labels to the learning algorithm for previously undetected patterns in a data set, leaving it on its own to find structure in its input.
Convolutional neural networks Class of deep neural networks, which have the particularity of being fully connected networks. It gives them the advantage of understanding the hierarchical pattern in data and assembling more complex patterns using smaller and simpler patterns.
Voxel Single sample, or data point, on a regularly spaced, three-dimensional grid. In CT scans, the values of voxels are Hounsfield units.
A voxel is a 3D pixel.
ROI (Region of Interest) Image areas containing the information relevant to image processing.
Skew of histogram Measure of the asymmetry of attenuation distribution.
The lung normal attenuation histogram is skewed to the left.
There is a decreased leftward skewness in IPF.
Kurtosis of histogram Measurement of how sharp an attenuation distribution curve is.
Kurtosis is abnormally low in idiopathic pulmonary fibrosis (IPF).
Threshold measurement Total count of pixels/voxels above or below a specific attenuation value that determines a relative volume.
Threshold measures in emphysema quantifies the extent of emphysema according to a specific index of −950 Hounsfield units (HU).
Texture analysis Statistical methods that evaluate spatial relationship between voxels in an ROI, in order to characterize textural features of the parenchyma and give information about heterogeneity.
As a young and developing tool in medicine, radiomics is still facing challenges that are limiting its wide use in clinical practice. Those include technical artifacts (inadequacy between acquisition and reconstruction, and inaccuracy in preprocessing procedures such as in segmentation), the lack of standard criteria to establish the accuracy of the results in the training and validation processes, and limited real-world experience in assessing the impact of quantitative imaging on clinical outcomes and diagnostic algorithm. Despite these limiting factors, research in the field is extensive, and should possibly and gradually establish radiomics as a clinical tool of major importance.
Applied to lung diseases, quantitative CT analysis extracts features such as threshold, histogram, and morphologic and texture analysis, and produces a quantifiable and reproducible evaluation of parenchymal changes. Radiomics has been used in the fields of nodules and cancer, obstructive and restrictive diseases, and infiltrative diseases (including idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, connective tissue-related interstitial lung disease and combined pulmonary fibrosis and emphysema (CPFE)).
The aim of this narrative review is to report the recent literature, and briefly summarize the interest of radiomics and Artificial intelligence (AI) in chest CT and their application in the field of pulmonary diseases, from a clinician’s perspective.

2. The Role of Radiomics in Lung Diseases

The application of radiomics in the field of lung diseases could lead to improvements in the clinical and paraclinical workflow in diagnosis, prognosis, management, follow-up and monitoring the response to treatment.

2.1. Lung Nodules

Lung nodules appearance provides a substantial clinical challenge, raising the question of diagnosis, prognosis and management. The detection of small nodules is known to be a difficult task. Indeed, the current diagnostic classification relies on size and growth rate as the main differentiators between benign and malignant nodules [2][3][4]. However, this approach is still imperfect and needs to be improved. Furthermore, the final diagnosis still relies on invasive biopsy.
Different research groups among the quantitative imaging network (QIN) [5] are currently developing radiomic models to describe nodules or tumors, based on size, shape, margins, texture and intensity. Their aim is to assess if the lesion is malignant or benign, and to determine its inherent prognosis, to evaluate its response to treatment and eventually to correlate imaging with genomics or histology. The application of artificial intelligence and radiomics in pulmonary nodule management is promising [6]. Studies of interest concerning radiomics and lung nodules are described in Table 2.
Table 2. Radiomics and lung nodules.
Study Description Cohort Performance
Chen et al. (2018) [7]
750 extracted features, among which 76 relevant features were selected
4-feature signature
Aim: nodule characterization
33 benign CT
42 malignant CT
Benign vs. malignant
Accuracy 84%
Sensitivity 92.85%
Specificity 72.73%
De Koning et al. (2020) [8]
15,792 patients, divided into a screening group (T0–T1 year–T2 years–T3 years) and a no-screening group
Follow-up of 10 years
Aim: nodule characterization through volume and VTD
15,792 patients Benign vs. malignant: impact on mortality
At 10 years, cancer mortality = 2.5 deaths/100,000 persons/years (screening group) vs. 3.3 deaths/100,000 (no-screening group)
Cumulative ratio 0.76 (p = 0.01)
Ma et al. (2016) [9]
583 extracted features
Random forest classifier
Aim: nodule characterization
36 benign CT
94 malignant CT
Benign vs. malignant
Accuracy 82.7%
Sensitivity 80%
Specificity 85.5%
Hawkins et al. (2016) [10]
219 extracted features, among which 23 showed concordance correlation > 0.95
Aim: nodule characterization
328 benign CT
170 malignant CT
Benign vs. malignant
Accuracy 80%
Huang et al. (2018) [11]
1108 extracted features
Aim: nodule characterization
Training cohort
70 benign CT
70 malignant CT
Validation cohort
26 benign CT
20 malignant CT
Benign vs. malignant
Accuracy 91%
Sensitivity 95%
Specificity 88%
Uthoff et al. (2020) [12]
Extracted features from nodule and perinodular parenchyma tissue
Aim: nodule characterization
Training cohort
289 benign CT
74 malignant CT
Validation cohort
50 benign CT
50 malignant CT
Benign vs. malignant
Accuracy 98%
Sensitivity 100%
Specificity 96%
Mao et al. (2019) [13]
385 extracted features
Comparison of radiomic model versus model of ACR Lung-RADS
Aim: nodule characterization
Training cohort
156 benign CT
40 malignant CT
Validation cohort
75 benign CT
23 malignant CT
Benign vs. malignant
Accuracy 89.8%
Sensitivity 81%
Specificity 92.2%
Maldonado et al. (2021) [14]
8-feature signature
Aim: to validate the BRODERS classifier (benign versus aggressive nodule evaluation using radiomic stratification) as a HRCT-based classifier for indeterminate pulmonary nodules
Validation cohort
91 malignant CT
79 benign CT
Benign vs. malignant
AUC 0.90
Sensitivity 92.3%
Specificity 62%
Mehta et al. (2021) [15]
1018 nodule CTs, malignancy rating from 1 to 5 according to volume
Fully supervised and semi-supervised classifiers
Aim: to reach an hybrid algorithm to estimate nodule malignancy by combining imagery and biomarkers/volumetric radiomic features
1018 CTs
Malignancy rating from 1 to 5
Benign vs. malignant
AUC 0.87 on fully supervised 3D CNN + random forest model (images, biomarkers and volumetric features)
AUC 0.93 on semi-supervised random forest (biomarkers only)
Digumarthy et al. (2019) [16]
92 extracted features
2 significant features at baseline
52 significant features at follow-up
Aim: nodule characterization according to temporal changes
31 benign CT
77 malignant CT
Benign vs. malignant according to temporal changes
AUC 0.741
Lee et al.
(2014) [17]
Clinical, thin-section CT and texture features
Aim: prediction of transient vs. persistent pattern of nodule
Transient PSNs
39 benign CT
Persistent PSNs
17 benign CT
30 malignant CT
Prediction of persistent part-solid nodules
AUC 0.93 if texture analysis was combined to clinical and CT features
Autrusseau et al. (2021) [18]
>1000 extracted features
Aim: to compare quantitative and qualitative concordance of pulmonary nodule risk assessment by radiomic software between full-dose (FD) chest CT and ultra-low-dose (ULD) chest CT
99 lung nodules
FD chest CT imaging
ULD chest CT imaging
Concordance between FD and ULD chest CT in radiomic-guided nodule risk assessment
ICC of 0.82, displaying a good agreement in malignancy similarity index between ULD and FD chest CT
Diagnosis. Apart from differentiating lung cancer from benign pulmonary nodules, thanks to nodule-size evaluation and texture-based analysis, radiomic analysis also extends its perspective to histological sub-typing among the same lesion, linking it to genomic information, and subsequently revealing prognostic and response to treatment evaluations. Several radiomic signatures that are able to accurately classify lung nodules have been published. For example, Chen et al. [7] defined a four-features radiomic signature, displaying an 84% accuracy in lung nodule classification. Additionally, the use of volumetric software leads to a more accurate and quantitative nodule sizing. In the same field, studying the volume doubling time (VTD) can lead to a better assessment of nodule growth rate. For example, a nodule with a VTD higher than 400–600 days has a 4.1% probability of malignancy, whereas a VTD lower than 400 days displays a malignancy probability of 9.7% [19]. Analysis of the NELSON trial results demonstrated that lung cancer mortality was significantly lower in high-risk patients who underwent volume CT screening (semi-automated extraction), than among those who underwent no screening [8]. Nodule texture can also be studied, empowering the accuracy with which radiomics can classify malignant and benign nodules. For example, Ma et al. [9] achieved an accuracy of 82.7%, and Hawkins et al. [10] demonstrated an accuracy of 80.0%. Other teams also reached relevant results [11][12]. Mao et al. [13] reported an overall accuracy of 89.8% in the qualitative diagnosis of small solitary pulmonary nodules (SSPNs), which outperformed the American College of Radiology (ACR) Lung-RADS approach [20]. Moreover, when texture analysis was combined to clinical and CT features, Lee et al. [17] demonstrated an improvement in the model performance (area under the curve, AUC), from 0.79 (clinical and CT features alone) to 0.93 (texture analysis incorporating clinical and CT features). Interestingly, there is a good concordance between the diagnostic abilities of radiomics software using ultra-low-dose chest CT compared to full-dose chest CT for lung nodule risk assessment, even if those are preliminary results [18]. Furthermore, Maldonado et al. [14] implemented and validated the BRODERS classifier (benign versus aggressive nodule evaluation using radiomic stratification), a high-resolution CT (HRCT)-based radiomic classifier in the characterization of indeterminate pulmonary nodules. Early works on convolutional neural networks (CNNs) compared to computer-aided detection/diagnosis (CAD) demonstrated a superiority of the radiomic approach in nodule classification, with a decrease in false positives, possibly reducing the need of several follow-ups [21][22][23]. Mehta et al. combined biomarkers, volumetric radiomics, and 3D CNNs to reach an algorithm classifying lung nodules [15]. Concerning histological subtyping, numerous studies have demonstrated the correlation between radiomic features and histology. For example, Wu et al. [24] described 53 radiomic features significantly associated with tumor histology, thus leading to an AUC of 0.72 in predicting the histological subtype. As discussed below (see “Section 2.2”), the possibility of radiomics to accurately predict the underlying gene expression of an identified tumor is also gathering considerable attention in recent years.
Prognosis. It has been shown that radiomic analysis performs well in the identification of nodules that are more at risk of evolution towards cancer. This has direct clinical implications, as it means shorter follow-up CT imaging and early detection of lung cancer. According to Digumarthy et al. [16], temporal changes in the radiomic features (process called delta-radiomics) of subsolid lung nodules indicates malignant etiology over benign. Indeed, they demonstrated that the radiomic features of benign nodules were stable over time, whereas the radiomic features of malignant nodules changed significantly between the baseline and follow-up CT, thus improving the accuracy up to 70.8% in the distinction between malignant and benign nodules with follow-up temporal changes.
One of the open questions that still remains is the sensitivity of quantitative imaging, and the correlation between imaging features computed with different segmentation algorithms. Indeed, segmentation algorithms ought to be highly reproducible, as the data extracted will serve for clinical purposes. Moreover, different segmentations might affect the radiomic features extraction. By performing a multicentric study based on a common set of reference images, Jayashree et al. [25] demonstrated a high correlation between groups of features (e.g., size and intensity features), whereas specific features within these groups did not correlate (e.g., reporting or not the size of airspaces within the lesion, affecting the mean intensity of the total nodule), uncovering subtle differences in the approach and calculations among the different centers. More research needs to be conducted to develop robust segmentation methods to provide accurate and reproducible nodule segmentation [26].

2.2. Cancer

Lung cancer is still the leading cause of death among neoplastic diseases in men and women worldwide [27]. The National Lung Cancer Screening Trial (NLST) demonstrated that CT screening in current and ex-smokers provides a significant survival benefit [28][29]. As of today, biopsies are still needed to establish the diagnosis and status of tumors. Nevertheless, this procedure is invasive and only reflects the characteristics of the part of the tumor from which the sample was obtained, considering that some tumors can be anatomically heterogeneous. Due to technological advances in AI, radiomic analysis could be seen as a virtual biopsy tool, and could have the potential to diagnose and determine tumor phenotypes. Radiomics has been used to assess tumor phenotypes using various imaging modalities, such as CT, MRI and PET CT [30]. Studies of interest, concerning radiomics and lung cancer, are described in Table 3.
Table 3. Radiomics and lung cancer.
Study Description Cohort Performance
Wu et al. (2016) [24]
440 extracted features
53 features associated with tumor histology
Aim: to predict cancer histopathology
Training cohort
198 malignant CT
Validation cohort
152 malignant CT
Tumor histology correlation
AUC 0.72
Yu et al. (2019) [31]
9 relevant features selected
Aim: to diagnose and predict pathologic stage in NSCLC
Training cohort
Validation cohort
Diagnosis and staging in NSCLC
AUC > 0.70, with predictive accuracy higher in lung adenocarcinoma than in lung squamous cell carcinoma
Liu et al. (2016) [32]
219 extracted radiomic features, among which 59 robust features were selected
Aim: search for correlation with EGFR mutation status in adenocarcinomas
298 malignant CT Prediction of mutation status
AUC EGFR+ status prediction 0.647, improved to 0.709 when adding a clinical model
Rios Velasquez et al. (2017) [33]
26 relevant features selected
Aim: search for correlation with KRAS and EGFR mutation status in adenocarcinomas
Training cohort
353 malignant CT
Validation cohort
352 malignant CT
Prediction of mutation status
AUC EGFR + versus EGFR− status 0.70
AUC KRAS + versus KRAS− status 0.63
AUC EGFR+ versus KRAS+ status 0.80
Tang et al. (2018) [34]
Pathology markers studied: CD3 count and %PDL1
490 extracted features, among which 12 robust features were selected, then targeted into 4 features to generate 4 clusters (immune-pathology informed model)
Aim: to predict immune modulator status in NSCLC
Training cohort
114 malignant CT
Validation cohort
176 malignant CT
Prediction of immune modulator status
Favorable outcome in low CT intensity and high heterogeneity with low PDL 1 and high CD3
Wu et al. (2020) [35]
18 relevant features selected
Comparison of radiomic models (ground-glass and solid features) with other models (Brock model, clinical semantic and volumetric models)
Aim: to predict invasiveness of lung adenocarcinoma by using ground-glass and solid features from part-solid nodules
Training cohort
Validation cohort
Prediction of invasiveness
AUC 0.98 for the model combining ground-glass and solid features
Improvement of 0.14 in AUC when adding ground-glass radiomic features to solid features
Coroller et al. (2015) [36]
445 extracted features, among which 35 relevant features were selected
Aim: to determine the capability of radiomic analysis to predict distant metastasis
Training cohort
98 malignant CT
Validation cohort
84 malignant CT
Prediction of distant metastasis
A multivariate radiomic signature (3 features) yielded a high prognostic performance for distant metastasis (CI 0.61)
He et al. (2019) [37]
519 extracted features, among which 35 relevant features were selected
Aim: to predict lymph node metastasis in resectable NSCLC
Training cohort
Validation cohort
Prediction of lymph node metastasis
Good discrimination for the model defining a radiomics-based predictive score (C index 0.785)
Ferreira et al. (2018) [38]
2777 extracted features, among which 100 most relevant features were selected
Aim: to predict lung cancer histopathology and metastases using machine learning models
Training cohort
52 malignant CT
Validation cohort
16 malignant CT
Histology and distant metastasis
AUC lymph nodal metastasis 0.89
AUC distant metastasis 0.97
AUC histopathology 0.92
Mattonen et al. (2016) [39]
104 extracted features, among which the 5 most relevant features were selected
Aim: to assess physicians’ ability to detect local recurrence versus radiomic tool
182 malignant CT Prediction of recurrence after SBRT
AUC 0.85 (radiomic signature of 5 features predicting local recurrence)
Coroller et al. (2016) [40]
15 relevant radiomic features selected
Aim: to assess if radiomics can predict response after neoadjuvant chemoradiation (NCT) in locally advanced NSCLC
127 malignant CT
Training cohort
Validation cohort
Prediction of response after NCT
AUC for pathologic gross residual disease prediction (7 features) > 0.6
AUC for pathologic complete response (1 feature) 0.63
AUC for poor response 0.63 (spherical disproportionality) or 0.61 (heterogeneous texture)
Kim et al. (2017) [41]
37 relevant radiomic features selected
Aim: to determine if radiomic features combined to conventional clinical features improved predictive performance in prediction of PFS in EGFR+ adenocarcinoma
48 malignant CT (NSCLC, EGFR mutant) Prediction of response to TKI
Addition of radiomics to clinical factors improved predictive performance of response to TKI (concordance index: combined model 0.77, clinical model 0.69; p < 0.0001)
Lafata et al. (2019) [42]
39 extracted features
Aim: to verify the hypothesis that lung texture, in addition to lung density, is partly responsible for correlation between PFT and CT imaging
64 malignant CT (NSCLC) Prediction of PFTs
Higher DLCO correlated with dense, heterogeneous pulmonary tissue (p < 0.002)
Lower FEV1 correlated with homogeneous, low attenuating pulmonary tissue (p < 0.03)
Diagnosis. Several studies have demonstrated the potential of radiomics in lung cancer diagnosis and staging [24][43][44][45][31]. Beyond anatomical characterization, radiomics could be used to predict the presence of particular mutations in genes. For example, Liu et al. and Zhang et al. [46][32] established a correlation between CT radiomic features and EGFR (epidermal growth factor receptor) mutation, whereas Rios Velazquez et al. [33] created a radiomic model to classify mutations in pulmonary adenocarcinoma. Weiss et al. [47] assessed the potential of textural analysis to radiologically differentiate K-RAS mutations from pan-wildtype tumors, reaching an accuracy of 89.6%. In the same perspective, Tang et al. [34] defined 12 robust radiomic features, generating an immune-pathology informed model to predict immune modulator status (interesting Cluster of differentiation 3 (CD3) and Programmed death-ligand 1 (PDL1)). Lastly, hypothesizing the fact that radiomics could provide histopathological analysis, while having the advantage of being non-invasive, Wu et al. [24] performed radiomic analysis to predict the histopathological types of non-small cell lung carcinoma (NSCLC), reaching a correlation with tumor histology of 0.72 (AUC). Additionally, another study demonstrated that separating ground-glass and solid CT radiomic features of part-solid nodules was useful in diagnosing the invasiveness of lung adenocarcinoma. Their radiomic model based on ground-glass and solid features yielded an AUC of 0.98 on the test data set, which was significantly higher than five other models tested (Brock University model, clinical semantic model, volumetric models, radiomic signature based solely on gross tumor volume (GTV) features, and perinodular features) [35].
Prognosis. Numerous studies corroborated the correlation between radiomic features and prognosis, in terms of the survival or occurrence of distant metastases [26][43][36][48][37][49][38]. For instance, Mattonen et al. [39] demonstrated the accuracy of radiomics to predict local recurrence in patients with early stage NSCLC, treated with stereotactic ablative radiotherapy. Their results also suggested that radiomics could detect early changes in the tumor, associated with local recurrence, which would not have been taken into account by clinicians.
Therapy. The use of radiomics to predict response to therapy was explored by several research groups, but has not yet been translated to clinical use [50][51]. Coroller et al. [40] studied pre-treatment radiomics data to determine if they could have predicted the response after neoadjuvant therapy in patients with locally advanced NSCLC. They found seven radiomic features that were predictive of residual disease (AUC > 0.6), and one radiomic feature that was predictive of a complete response (AUC 0.63). Similarly, Kim et al. [41] used radiomic analysis in combination with conventional clinical features to predict the response to tyrosine kinase inhibitors (TKI) in epidermal growth factor receptor (EGFR) mutant NSCLC, achieving a good predictive performance, with a concordance index of 0.77.
Despite facing limitations inherent to its novelty (see “Section 3”), radiomics is seen as a revolutionary precision medicine approach in lung cancer. Its applications, as follow, in the field of research are broad and extensive: diagnosis, staging and prognosis, prediction of treatment response, and disease monitoring [52]. These characteristics are highly interesting, as lung cancer can face a rapid progression, but studies are still needed to reach real-life clinical application.

2.3. Obstructive Lung Diseases

In current clinical practice, pulmonary function tests are crucial to assess the characteristics of obstructive lung diseases. However, while being useful in assessing respiratory performance, as well as volume and resistance ranges, they cannot inform the clinician about the local extent of emphysema or air trapping. Overcoming this anatomical deficiency, quantitative CT analysis can be used, and extensive research has been carried out to automate the quantification of emphysema or air trapping severity and distribution [53][54], as well as to characterize airway diseases more precisely [55].
In this way, quantitative CT analysis and radiomics could be applied to various obstructive lung diseases, such as in the characterization of chronic obstructive pulmonary disease (COPD) or asthma, the detection of bronchiolitis obliterans, or even in planning eventual emphysema reduction therapy.
In obstructive pulmonary diseases, the lung texture and density are influenced by increased air abundance, compared to normal lungs. The origin of this excess of air plethora can be anatomical (emphysema) or functional (air trapping). In addition, the study of lung texture and density is highly biased by the respiratory phase [56]. During inspiration, the CT appearance of emphysema can be characterized by the following two methods: areas with a parenchyma density < −950 HU (emphysema index: percentage of parenchyma below attenuation threshold of −950 HU) [57], or areas related to the lowest 15th percentile (emphysema index: lung voxels below threshold value in HU, for which 15% of all lung voxels have a decreased attenuation value on the attenuation histogram) [58]. During expiration, air trapping can be defined as the area with a parenchyma density < −856 HU on expiratory CT. However, it might be difficult to differentiate low attenuation from air trapping versus low attenuation from emphysema. To address this issue, Pompe et al. [59] applied parametric response mapping (PRM), a method using a combination of threshold-based measures taken simultaneously during inspiratory and expiratory phases on co-registered CT, allowing a biphasic characterization of voxels.
Parallel to parenchyma characterization, quantitative analysis of airways can be realized up to the fifth bronchial generation. Quantitative CT metrics of airways include the study of wall thickness, area and density, and lumen diameter and area. However, its use faces a certain number of limitations, as airway metrics are highly influenced by lung volume, aging and inflammation [60]. Therefore, applying airway metrics in clinical practice is still at the preliminary stage.

2.3.1. COPD

Diagnosis. Applying radiomics could lead to better COPD characterization and quantification [61][62]. Lynch et al. [63] used an integrative description of the visual and quantitative evaluation of CT images in COPD to determine COPD phenotypes, and classified them into emphysema-predominant subtypes (six different subclassifications) and airway-predominant subtypes (two subclassifications). Beyond the classical anatomical characterization, several research groups demonstrated the potential of CT radiomics features to correlate with lung function [42][64].
Prognosis. Cho et al. performed a radiomic analysis to predict survival and apply risk stratification in COPD, and reached a five-feature model displaying a C-index of 0.774, accurately identifying patients with an increased risk of mortality [65]. Interestingly, CT vascular features can also be helpful in the characterization of COPD, as the quantitative assessment of pulmonary vascular alterations in COPD patients exhibited correlations with clinical parameters, such as pulmonary function tests (PFTs) and survival, in the The Korean Obstructive Lung Disease (KOLD) cohort [66].
Therapy. Quantitative CT analysis can also be used to assess the progression of emphysema in alpha-1-antitrypsin deficiency and the response to augmentation therapy [67]. Moreover, the assessment of lung lesions in emphysema, by CT quantification and perfusion scintigraphy, implements the best prediction of outcome in lung volume reduction (LVR) as a therapeutic option [68][69].

2.3.2. Asthma

Asthma phenotyping is of utmost importance for disease categorization and personalized treatment. In this context, airway remodeling is seen as a possible imaging biomarker. Quantitative imaging led to the definition of asthma clusters, which were found to respond differently to the bronchodilator between the different imaging clusters [70]. Further characterization has been possible with the quantification of air trapping. For example, Choi et al. [71] found that four radiological clusters had differences in their response to high-dose inhaled corticosteroids (ICS). Quantitative CT analysis in asthma can also be used as a novel marker to predict or assess the response to treatment, which can lead to more personalized therapy [71][72].

2.4. Interstitial Lung Diseases

As a heterogeneous group of pathologically distinct processes, but sometimes radiologically overlapping entities, interstitial lung diseases (ILD) can represent a diagnostic challenge and face an unpredictable clinical course. Combined to biological data and PFTs, thin-section chest CT is essential in differentiating interstitial lung diseases, evaluating their severity and evolution over time, and possibly monitoring their response to therapy. Nevertheless, visual assessments of thin-section CT and traditional PFTs evaluation are relatively insensitive to slight changes or early disease. Moreover, visual evaluation of HRCT pattern is highly subjective and variable, even among experts. The finest analysis of specific radiological patterns, such as ground-glass opacities, honeycombing, traction bronchiectasis, attenuation and reticular density, and their volumetric distribution and spatial relationships, can lead to more precise diagnosis. Therefore, the contribution of radiomics, as a reproducible and accurate imaging tool, is a major issue. Some studies also reported a strong correlation between radiomic features in ILD and pulmonary function tests. Studies of interest, concerning radiomics and interstitial lung diseases, are described in Table 4.
Table 4. Radiomics and interstitial lung diseases.
Study Description Cohort Performance
Schniering et al. (2019) [73]
154 radiomic features extracted
Aim: to evaluate the potential of CT radiomics features for staging experimental ILD and assess transferability to human ILD
66 ILD CT (20 mild ILD and 46 advanced ILD) Staging of ILD (proof of concept)
AUC 0.929
Stefano et al. (2020) [74]
Extraction of 10 HRCT parameters
Aim: to assess the diagnostic performance of radiomic features in IPF
32 IPF CT Severity of IPF
NL (normally attenuated lung) at -200 HU demonstrated the strongest correlation with disease severity (p = 0.009)
Martini et al. (2020) [75]
1116 extracted radiomic features
Aim: to retrospectively evaluate if radiomics features are able to detect ILD and distinguish the stages in SSc
66 SSc CT
Training cohort
Validation cohort
Severity and staging of SSc-ILD
Radiomics features can predict GAP stage with a sensitivity of 84% and a specificity of almost 100%. AUC 0.96.
Correlation of radiomics with GAP stage (but not with the visually defined features of ILD-HRCT)
Ungprasert et al. (2017) [76]
Extraction of quantitative CT indexes with CALIPER
Aim: To evaluate the correlation between
Quantitative HRCT analysis with CALIPER software and pulmonary function tests (PFTs) in patients with idiopathic inflammatory myopathies (IIM)-associated interstitial lung disease (ILD).
110 ILD CT
110 baseline CT
110 1-year follow-up CT
Correlation with PFTs in IIM associated ILD
Baseline: Ground-glass opacities and reticular density had a significant negative correlation with diffusing capacity for carbon monoxide (DLCO), total lung capacity (TLC), and oxygen saturation
1 year: changes in total interstitial abnormalities had a significant negative correlation with changes in TLC and oxygen saturation
Kim et al. (2015) [77]
Extraction of quantitative CT indexes (MLA, variance, skewness, kurtosis, median)
Aim: to compare known CT histogram kurtosis and a classifier-based quantitative score to assess baseline severity and change over time in patients with IPF.
57 IPF patients
57 baseline CT
57 7-months follow-up CT
Correlation with baseline lung function and prediction of evolution in IPF
All baseline histogram indices (texture features) and QLF and QILD scores were correlated well with baseline FVC and DLCO
When assessing associations with changes in FVC and DLCO over time, only QLF score was statistically significant (r = −0.57; p < 0.0001 for FVC and r = −0.34; p = 0.025 for DLCO), whereas kurtosis was not.
De Giacomi et al. (2017) [78]
Extraction of quantitative CT indexes with CALIPER
Aim: to use quantitative CT analysis to differentiate NSIP versus IPF and assess long-term survival
40 biopsy-confirmed UIP
20 biopsy-confirmed NSIP
Differentiation NSIP vs. IPF
Compared with NSIP, IPF patients experienced greater functional decline (CVF, p = 0.02) and radiologic progression (reticulation volume, p = 0.048).
Both baseline and short-term changes in quantitative radiologic findings were predictive of mortality.
Lee et al. (2018) [79]
Aim: to assess quantitative imaging in the evaluation of lymph nodes in pulmonary sarcoidosis and tuberculosis
26 CT from tubrcolosis patients, 21 CT from sarcoidosis patients. Differentiation between tuberculosis and sarcoidosis LN
Significant differences in the values of the Feret’s diameter, perimeter, area, circularity, mean grey value, SD, median, skewness, and kurtosis between tuberculous and sarcoid LNs (p < 0.05)
Best et al. (2008) [80]
Extraction of quantitative CT indexes (MLA, skewness, kurtosis) and visual scores (fibrosis, GGO, emphysema)
Aim: to retrospectively evaluate quantitative CT indexes as predictors of mortality and describe 12-months changes in CT in IPF patients
167 IPF patients
167 baseline CT
167 1-year follow-up CT
Prediction of mortality and progression in IPF
FVC (p = 0.006) and fibrosis (p = 0.002) were predictors of short-term mortality
Fibrosis index (p = 0.03), Mean Lung attenuation (p = 0.003), skewness (p < 0.001) and kurtosis (p < 0.001) predicted disease progression
Maldonado et al. (2014) [81]
Extraction of quantitative CT indexes and their mean volumetric quantification
Aim: to verify the hypothesis that short-term radiological changes may be predictive of survival by the use of novel software tool CALIPER (computer-aided lung informatics for pathology evaluation and rating)
55 IPF patients Correlation between CT changes and mortality in IPF
Interval change in quantitative volumetrics (p < 0.05) as quantified by CALIPER were predictive of survival after a median follow-up of 2.4 years
Jacob et al. (2017) [82]
Extraction of quantitative CT indexes to define a quantitative lung fibrosis score (QLF)
Aim: to compare computer algorithm CALIPER to convention CT and PFTs for mortality prediction in IPF
283 IPF CT Prediction of mortality in IPF
Independent predictors of mortality were CPI “composite physiologic index” (p < 0.001) and the following two CALIPER parameters: pulmonary vessel volume (p = 0.001) and honeycombing (p = 0.002)
Kim et al. (2011) [83]
Extraction of quantitative CT indexes
Aim: to assess the efficacy of cyclophosphamide in SSc-ILD using texture-based scores (impact on QLF)
83 baseline CT
83 1-year follow-up CT
Evaluate the effectiveness of cyclophosphamide in SSc-ILD
Difference in whole-lung QLF was ~5% (p = 0.0190).
Significant associations between changes in QLF and FVC (r = −0.33), dyspnea score (r = −0.29), and consensus visual score (p = 0.0001).
Diagnosis. Many studies have demonstrated the performance of quantitative CT analysis and its potential to assess the severity of ILD [84][73]. In IPF, Stefano et al. [74] demonstrated a strong correlation between radiological features and disease severity (p = 0.009). In scleroderma-related ILD, Martini et al. [75] used radiomics to detect ILD in sclerodermic patients and to predict their GAP (Gender, Age, Physiology) stage, as generally used in ILD evaluation (AUC 0.96). Many teams also determined correlations between quantitative radiological features and baseline PFTs [76][77]. One remaining recurrent matter of concern is the discernment between IPF and fibrosing non-specific interstitial pneumonia (NSIP). A recent study addressed this issue by using a CALIPER tool (computer-aided lung informatics for pathology evaluation and rating), combining PFTs and quantitative imaging to significantly discriminate NSIP from IPF [78]. Among other diagnostic issues, identifying the nature of mediastinal lymphadenopathy without recourse to a biopsy, in order to differentiate sarcoidosis and tuberculosis, remains challenging. Lee et al. [79] used quantitative imaging to discriminate sarcoidosis from tuberculosis lymphadenopathy, displaying significant differences in quantitative CT features between the two groups. All these studies make us consider the distant utopia of reaching a fully virtual biopsy, in which no tissue sample would be needed to obtain the same histological information, even if research and its clinical application are still at a preliminary stage.
Prognosis. The comparison of changes in radiological features led many teams to prove that radiomic features could predict the evolution of lung function, disease progression or mortality in ILD. In their study, by evaluating quantitative CT indexes and lung function, Best et al. [80] showed that forced vital capacity (FVC) and fibrosis index were predictors of short-term mortality in IPF, whereas more precise features (fibrosis index, mean lung attenuation, skewness and kurtosis) predicted disease progression. This is in line with the findings of Kim et al. [77], who demonstrated that quantitative lung fibrosis (QLF) score correlated well with changes in PFTs and disease progression in IPF. In the same perspective, other teams [81][82] used the CALIPER tool (computer-aided lung informatics for pathology evaluation and rating) to predict survival in IPF.
Therapy. Concerning the monitoring of response to therapy in ILD, few studies are currently available. Proving the usefulness of radiomics in this precise field, Kim et al. [83] assessed the efficacy of cyclophosphamide in scleroderma-related ILD, by using texture-based scores determining the QLF score. They established a significant change in QLF score after treatment, supporting the efficacy of cyclophosphamide over placebo, and also demonstrated a significant association between changes in QLF score, forced vital capacity (FVC) and dyspnea score. These few results, already promising, are the first signs of what radiomics could bring in the precise and quantifiable evaluation of the response to treatment in ILD.

2.5. Vascular Lung Diseases

The application of artificial intelligence in the field of vascular lung diseases is still at the preliminary stages. Only a few studies report results and mainly focus on pulmonary hypertension (PH). For example, Kiely et al. [85] managed to apply artificial intelligence in order to achieve a predictive model, using existing and real-world data to determine patients at high risk of idiopathic pulmonary hypertension, resulting in 99.99% specificity and 14.10% sensitivity.
However, it is strongly believed that AI and machine learning could be of high interest in the diagnostic and prognostic classification of PH. For instance, one area of research is the accurate segmentation of cardiac chambers on MRI or CT, and the segmentation of the pulmonary vascular network [86][87]. One notable current limitation of imaging is the inability to properly assess distal pulmonary arterial vasculature, which is the pathological site interesting pulmonary arterial hypertension (PAH). Therefore, applying radiomics on CT or MRI imaging could lead to a more accurate evaluation of pulmonary perfusion [88]. Lastly, as PH diagnosis still relies on right heart catheterization (RHC), any non-invasive diagnostic tool could be highly welcomed. Lungu et al. [89] hypothesized that combining mathematical and cardiopulmonary metrics with AI classifiers could add diagnostic value. Their classifier showed that 92% of patients were correctly classified, which led to the conclusion that combining the PH biomarker with AI classification algorithms enhanced the diagnostic performance of non-invasive techniques in PH.

2.6. Pleural Diseases

The rare studies exploring the pleura from a radiomic perspective only concern pleural tumor invasion in lung cancer. For example, Yang et al. [90] exposed a strong association between tumor imaging phenotype, as defined by radiomic features, and dry pleural dissemination. Studies are still needed in the field of radiomics, applied to benign or malignant primitive pleural diseases.


  1. Lambin, P.; Rios-Velazquez, E.; Leijenaar, R.; Carvalho, S.; van Stiphout, R.G.P.M.; Granton, P.; Zegers, C.M.L.; Gillies, R.; Boellard, R.; Dekker, A.; et al. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 2012, 48, 441–446.
  2. Wilson, D.O.; Ryan, A.; Fuhrman, C.; Schuchert, M.; Shapiro, S.; Siegfried, J.M.; Weissfeld, J. Doubling Times and CT Screen–Detected Lung Cancers in the Pittsburgh Lung Screening Study. Am. J. Respir. Crit. Care Med. 2012, 185, 85–89.
  3. Hasegawa, M.; Sone, S.; Takashima, S.; Li, F.; Yang, Z.G.; Maruyama, Y.; Watanabe, T. Growth rate of small lung cancers detected on mass CT screening. Br. J. Radiol. 2000, 73, 1252–1259.
  4. Ko, J.P.; Berman, E.J.; Kaur, M.; Babb, J.S.; Bomsztyk, E.; Greenberg, A.K.; Naidich, D.P.; Rusinek, H. Pulmonary Nodules: Growth Rate Assessment in Patients by Using Serial CT and Three-dimensional Volumetry. Radiology 2012, 262, 662–671.
  5. Nordstrom, R.J. The Quantitative Imaging Network in Precision Medicine. Tomography 2016, 2, 239–241.
  6. Ather, S.; Kadir, T.; Gleeson, F. Artificial intelligence and radiomics in pulmonary nodule management: Current status and future applications. Clin. Radiol. 2020, 75, 13–19.
  7. Chen, C.-H.; Chang, C.-K.; Tu, C.-Y.; Liao, W.-C.; Wu, B.-R.; Chou, K.-T.; Chiou, Y.-R.; Yang, S.-N.; Zhang, G.; Huang, T.-C. Radiomic features analysis in computed tomography images of lung nodule classification. PLoS ONE 2018, 13, e0192002.
  8. de Koning, H.J.; van der Aalst, C.M.; de Jong, P.A.; Scholten, E.T.; Nackaerts, K.; Heuvelmans, M.A.; Lammers, J.-W.J.; Weenink, C.; Yousaf-Khan, U.; Horeweg, N.; et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 2020, 382, 503–513.
  9. Ma, J.; Wang, Q.; Ren, Y.; Hu, H.; Zhao, J. Automatic lung nodule classification with radiomics approach. In Medical Imaging 2016: PACS and Imaging Informatics: Next Generation and Innovations; Zhang, J., Cook, T.S., Eds.; International Society for Optics and Photonics: San Diego, CA, USA, 2016; p. 978906. Available online: (accessed on 21 June 2021).
  10. Hawkins, S.; Wang, H.; Liu, Y.; Garcia, A.; Stringfield, O.; Krewer, H.; Li, Q.; Cherezov, D.; Gatenby, R.A.; Balagurunathan, Y.; et al. Predicting Malignant Nodules from Screening CT Scans. J. Thorac. Oncol. 2016, 11, 2120–2128.
  11. Huang, P.; Park, S.; Yan, R.; Lee, J.; Chu, L.C.; Lin, C.T.; Hussien, A.; Rathmell, J.; Thomas, B.; Chen, C.; et al. Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. Radiology 2018, 286, 286–295.
  12. Uthoff, J.; Stephens, M.J.; Newell, J.D.; Hoffman, E.A.; Larson, J.; Koehn, N.; De Stefano, F.A.; Lusk, C.M.; Wenzlaff, A.S.; Watza, D.; et al. Machine learning approach for distinguishing malignant and benign lung nodules utilizing standardized perinodular parenchymal features from CT. Med. Phys. 2019, 46, 3207–3216.
  13. Mao, L.; Chen, H.; Liang, M.; Li, K.; Gao, J.; Qin, P.; Ding, X.; Li, X.; Liu, X. Quantitative radiomic model for predicting malignancy of small solid pulmonary nodules detected by low-dose CT screening. Quant. Imaging Med. Surg. 2019, 9, 263–272.
  14. Maldonado, F.; Varghese, C.; Rajagopalan, S.; Duan, F.; Balar, A.B.; Lakhani, D.A.; Antic, S.L.; Massion, P.P.; Johnson, T.F.; Karwoski, R.A.; et al. Validation of the BRODERS classifier (Benign versus aggRessive nODule Evaluation using Radiomic Stratification), a novel HRCT-based radiomic classifier for indeterminate pulmonary nodules. Eur. Respir. J. 2021, 57, 2002485.
  15. Mehta, K.; Jain, A.; Mangalagiri, J.; Menon, S.; Nguyen, P.; Chapman, D.R. Lung Nodule Classification Using Biomarkers, Volumetric Radiomics, and 3D CNNs. J. Digit. Imaging 2021.
  16. Digumarthy, S.R.; Padole, A.M.; Rastogi, S.; Price, M.; Mooradian, M.J.; Sequist, L.V.; Kalra, M.K. Predicting malignant potential of subsolid nodules: Can radiomics preempt longitudinal follow up CT? Cancer Imaging 2019, 19, 36.
  17. Lee, S.H.; Lee, S.M.; Goo, J.M.; Kim, K.-G.; Kim, Y.J.; Park, C.M. Usefulness of Texture Analysis in Differentiating Transient from Persistent Part-solid Nodules(PSNs): A Retrospective Study. PLoS ONE 2014, 9, e85167.
  18. Autrusseau, P.-A.; Labani, A.; De Marini, P.; Leyendecker, P.; Hintzpeter, C.; Ortlieb, A.-C.; Calhoun, M.; Goldberg, I.; Roy, C.; Ohana, M. Radiomics in the evaluation of lung nodules: Intrapatient concordance between full-dose and ultra-low-dose chest computed tomography. Diagn. Interv. Imaging 2021, 102, 233–239.
  19. Horeweg, N.; van der Aalst, C.M.; Vliegenthart, R.; Zhao, Y.; Xie, X.; Scholten, E.T.; Mali, W.; Thunnissen, E.; Weenink, C.; Groen, H.J.M.; et al. Volumetric computed tomography screening for lung cancer: Three rounds of the NELSON trial. Eur. Respir. J. 2013, 42, 1659–1667.
  20. ACR. Lung CT Screening Reporting & Data System (Lung-RADS). Available online: (accessed on 20 April 2021).
  21. Murphy, A.; Skalski, M.; Gaillard, F. The utilisation of convolutional neural networks in detecting pulmonary nodules: A review. Br. J. Radiol. 2018, 91, 20180028.
  22. da Silva, G.L.F.; Valente, T.L.A.; Silva, A.C.; de Paiva, A.C.; Gattass, M. Convolutional neural network-based PSO for lung nodule false positive reduction on CT images. Comput. Methods Programs Biomed. 2018, 162, 109–118.
  23. Li, S.; Xu, P.; Li, B.; Chen, L.; Zhou, Z.; Hao, H.; Duan, Y.; Folkert, M.; Ma, J.; Huang, S.; et al. Predicting lung nodule malignancies by combining deep convolutional neural network and handcrafted features. Phys. Med. Biol. 2019, 64, 175012.
  24. Wu, W.; Parmar, C.; Grossmann, P.; Quackenbush, J.; Lambin, P.; Bussink, J.; Mak, R.; Aerts, H.J.W.L. Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology. Front. Oncol. 2016, 6, 71.
  25. Radiomics of Lung Nodules: A Multi-Institutional Study of Robustness and Agreement of Quantitative Imaging Features. Tomography 2016, 2, 430–437.
  26. Balagurunathan, Y.; Gu, Y.; Wang, H.; Kumar, V.; Grove, O.; Hawkins, S.; Kim, J.; Goldgof, D.B.; Hall, L.O.; Gatenby, R.A.; et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Transl. Oncol. 2014, 7, 72–87.
  27. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  28. The National Lung Screening Trial Research Team Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011, 365, 395–409.
  29. National Lung Screening Trial Research Team Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2019, 14, 1732–1742.
  30. Refaee, T.; Wu, G.; Ibrahim, A.; Halilaj, I.; Leijenaar, R.T.H.; Rogers, W.; Gietema, H.A.; Hendriks, L.E.L.; Lambin, P.; Woodruff, H.C. The Emerging Role of Radiomics in COPD and Lung Cancer. Respiration 2020, 99, 99–107.
  31. Yu, L.; Tao, G.; Zhu, L.; Wang, G.; Li, Z.; Ye, J.; Chen, Q. Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis. BMC Cancer 2019, 19, 464.
  32. Liu, Y.; Kim, J.; Balagurunathan, Y.; Li, Q.; Garcia, A.L.; Stringfield, O.; Ye, Z.; Gillies, R.J. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. Clin. Lung Cancer 2016, 17, 441–448.e6.
  33. Rios Velazquez, E.; Parmar, C.; Liu, Y.; Coroller, T.P.; Cruz, G.; Stringfield, O.; Ye, Z.; Makrigiorgos, M.; Fennessy, F.; Mak, R.H.; et al. Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. Cancer Res. 2017, 77, 3922–3930.
  34. Tang, C.; Hobbs, B.; Amer, A.; Li, X.; Behrens, C.; Canales, J.R.; Cuentas, E.P.; Villalobos, P.; Fried, D.; Chang, J.Y.; et al. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci. Rep. 2018, 8, 1922.
  35. Wu, G.; Woodruff, H.C.; Shen, J.; Refaee, T.; Sanduleanu, S.; Ibrahim, A.; Leijenaar, R.T.H.; Wang, R.; Xiong, J.; Bian, J.; et al. Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study. Radiology 2020, 297, E282.
  36. Coroller, T.P.; Grossmann, P.; Hou, Y.; Rios Velazquez, E.; Leijenaar, R.T.H.; Hermann, G.; Lambin, P.; Haibe-Kains, B.; Mak, R.H.; Aerts, H.J.W.L. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother. Oncol. 2015, 114, 345–350.
  37. He, L.; Huang, Y.; Yan, L.; Zheng, J.; Liang, C.; Liu, Z. China Radiomics-based predictive risk score: A scoring system for preoperatively predicting risk of lymph node metastasis in patients with resectable non-small cell lung cancer. Chin. J. Cancer Res. 2019, 31, 641–652.
  38. Ferreira Junior, J.R.; Koenigkam-Santos, M.; Cipriano, F.E.G.; Fabro, A.T.; Azevedo-Marques, P.M. de Radiomics-based features for pattern recognition of lung cancer histopathology and metastases. Comput. Methods Programs Biomed. 2018, 159, 23–30.
  39. Mattonen, S.A.; Palma, D.A.; Johnson, C.; Louie, A.V.; Landis, M.; Rodrigues, G.; Chan, I.; Etemad-Rezai, R.; Yeung, T.P.C.; Senan, S.; et al. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. Int. J. Radiat. Oncol. 2016, 94, 1121–1128.
  40. Coroller, T.P.; Agrawal, V.; Narayan, V.; Hou, Y.; Grossmann, P.; Lee, S.W.; Mak, R.H.; Aerts, H.J.W.L. Radiomic phenotype features predict pathological response in non-small cell lung cancer. Radiother. Oncol. 2016, 119, 480–486.
  41. Kim, H.; Park, C.M.; Keam, B.; Park, S.J.; Kim, M.; Kim, T.M.; Kim, D.-W.; Heo, D.S.; Goo, J.M. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE 2017, 12, e0187500.
  42. Lafata, K.J.; Zhou, Z.; Liu, J.-G.; Hong, J.; Kelsey, C.R.; Yin, F.-F. An Exploratory Radiomics Approach to Quantifying Pulmonary Function in CT Images. Sci. Rep. 2019, 9, 11509.
  43. Aerts, H.J.W.L.; Velazquez, E.R.; Leijenaar, R.T.H.; Parmar, C.; Grossmann, P.; Carvalho, S.; Cavalho, S.; Bussink, J.; Monshouwer, R.; Haibe-Kains, B.; et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun. 2014, 5, 4006.
  44. Maldonado, F.; Boland, J.M.; Raghunath, S.; Aubry, M.C.; Bartholmai, B.J.; Deandrade, M.; Hartman, T.E.; Karwoski, R.A.; Rajagopalan, S.; Sykes, A.-M.; et al. Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)—A pilot study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2013, 8, 452–460.
  45. Liu, Y.; Balagurunathan, Y.; Atwater, T.; Antic, S.; Li, Q.; Walker, R.C.; Smith, G.T.; Massion, P.P.; Schabath, M.B.; Gillies, R.J. Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017, 23, 1442–1449.
  46. Zhang, L.; Chen, B.; Liu, X.; Song, J.; Fang, M.; Hu, C.; Dong, D.; Li, W.; Tian, J. Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. Transl. Oncol. 2018, 11, 94–101.
  47. Weiss, G.J.; Ganeshan, B.; Miles, K.A.; Campbell, D.H.; Cheung, P.Y.; Frank, S.; Korn, R.L. Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic. PLoS ONE 2014, 9, e100244.
  48. Song, J.; Liu, Z.; Zhong, W.; Huang, Y.; Ma, Z.; Dong, D.; Liang, C.; Tian, J. Non-small cell lung cancer: Quantitative phenotypic analysis of CT images as a potential marker of prognosis. Sci. Rep. 2016, 6, 38282.
  49. Hosny, A.; Parmar, C.; Coroller, T.P.; Grossmann, P.; Zeleznik, R.; Kumar, A.; Bussink, J.; Gillies, R.J.; Mak, R.H.; Aerts, H.J.W.L. Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study. PLOS Med. 2018, 15, e1002711.
  50. Chetan, M.R.; Gleeson, F.V. Radiomics in predicting treatment response in non-small-cell lung cancer: Current status, challenges and future perspectives. Eur. Radiol. 2021, 31, 1049–1058.
  51. Bera, K.; Velcheti, V.; Madabhushi, A. Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 1008–1018.
  52. Limkin, E.J.; Sun, R.; Dercle, L.; Zacharaki, E.I.; Robert, C.; Reuzé, S.; Schernberg, A.; Paragios, N.; Deutsch, E.; Ferté, C. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann. Oncol. 2017, 28, 1191–1206.
  53. Gevenois, P.A.; de Maertelaer, V.; De Vuyst, P.; Zanen, J.; Yernault, J.C. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 1995, 152, 653–657.
  54. Madani, A.; Zanen, J.; de Maertelaer, V.; Gevenois, P.A. Pulmonary emphysema: Objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry. Radiology 2006, 238, 1036–1043.
  55. de Jong, P.A.; Müller, N.L.; Paré, P.D.; Coxson, H.O. Computed tomographic imaging of the airways: Relationship to structure and function. Eur. Respir. J. 2005, 26, 140–152.
  56. Madani, A.; Van Muylem, A.; Gevenois, P.A. Pulmonary Emphysema: Effect of Lung Volume on Objective Quantification at Thin-Section CT. Radiology 2010, 257, 260–268.
  57. Bankier, A.A.; De Maertelaer, V.; Keyzer, C.; Gevenois, P.A. Pulmonary Emphysema: Subjective Visual Grading versus Objective Quantification with Macroscopic Morphometry and Thin-Section CT Densitometry. Radiology 1999, 211, 851–858.
  58. Mohamed Hoesein, F.A.A.; de Hoop, B.; Zanen, P.; Gietema, H.; Kruitwagen, C.L.J.J.; van Ginneken, B.; Isgum, I.; Mol, C.; van Klaveren, R.J.; Dijkstra, A.E.; et al. CT-quantified emphysema in male heavy smokers: Association with lung function decline. Thorax 2011, 66, 782–787.
  59. Pompe, E.; van Rikxoort, E.M.; Schmidt, M.; Rühaak, J.; Estrella, L.G.; Vliegenthart, R.; Oudkerk, M.; de Koning, H.J.; van Ginneken, B.; de Jong, P.A.; et al. Parametric response mapping adds value to current computed tomography biomarkers in diagnosing chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015, 191, 1084–1086.
  60. Hackx, M.; Francotte, D.; Garcia, T.S.; Van Muylem, A.; Walsdorff, M.; Gevenois, P.A. Effect of total lung capacity, gender and height on CT airway measurements. Br. J. Radiol. 2017, 90, 20160898.
  61. Ginsburg, S.B.; Lynch, D.A.; Bowler, R.P.; Schroeder, J.D. Automated Texture-based Quantification of Centrilobular Nodularity and Centrilobular Emphysema in Chest CT Images. Acad. Radiol. 2012, 19, 1241–1251.
  62. Martini, K.; Frauenfelder, T. Advances in imaging for lung emphysema. Ann. Transl. Med. 2020, 8, 1467.
  63. Lynch, D.A.; Austin, J.H.M.; Hogg, J.C.; Grenier, P.A.; Kauczor, H.-U.; Bankier, A.A.; Barr, R.G.; Colby, T.V.; Galvin, J.R.; Gevenois, P.A.; et al. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. Radiology 2015, 277, 192–205.
  64. Occhipinti, M.; Paoletti, M.; Bartholmai, B.J.; Rajagopalan, S.; Karwoski, R.A.; Nardi, C.; Inchingolo, R.; Larici, A.R.; Camiciottoli, G.; Lavorini, F.; et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir. Res. 2019, 20, 101.
  65. Cho, Y.H.; Seo, J.B.; Lee, S.M.; Kim, N.; Yun, J.; Hwang, J.E.; Lee, J.S.; Oh, Y.-M.; Do Lee, S.; Loh, L.-C.; et al. Radiomics approach for survival prediction in chronic obstructive pulmonary disease. Eur. Radiol. 2021.
  66. Cho, Y.H.; Lee, S.M.; Seo, J.B.; Kim, N.; Bae, J.P.; Lee, J.S.; Oh, Y.-M.; Do-Lee, S. Quantitative assessment of pulmonary vascular alterations in chronic obstructive lung disease: Associations with pulmonary function test and survival in the KOLD cohort. Eur. J. Radiol. 2018, 108, 276–282.
  67. Stockley, R.A.; Parr, D.G.; Piitulainen, E.; Stolk, J.; Stoel, B.C.; Dirksen, A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: An integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir. Res. 2010, 11, 136.
  68. Chandra, D.; Lipson, D.A.; Hoffman, E.A.; Hansen-Flaschen, J.; Sciurba, F.C.; DeCamp, M.M.; Reilly, J.J.; Washko, G.R. Perfusion Scintigraphy and Patient Selection for Lung Volume Reduction Surgery. Am. J. Respir. Crit. Care Med. 2010, 182, 937–946.
  69. Milanese, G.; Silva, M.; Sverzellati, N. Lung volume reduction of pulmonary emphysema: The radiologist task. Curr. Opin. Pulm. Med. 2016, 22, 179–186.
  70. Gupta, S.; Hartley, R.; Khan, U.T.; Singapuri, A.; Hargadon, B.; Monteiro, W.; Pavord, I.D.; Sousa, A.R.; Marshall, R.P.; Subramanian, D.; et al. Quantitative computed tomography–derived clusters: Redefining airway remodeling in asthmatic patients. J. Allergy Clin. Immunol. 2014, 133, 729–738.e18.
  71. Choi, S.; Hoffman, E.A.; Wenzel, S.E.; Castro, M.; Fain, S.; Jarjour, N.; Schiebler, M.L.; Chen, K.; Lin, C.-L. Quantitative computed tomographic imaging–based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes. J. Allergy Clin. Immunol. 2017, 140, 690–700.e8.
  72. Tunon-de-Lara, J.-M.; Laurent, F.; Giraud, V.; Perez, T.; Aguilaniu, B.; Meziane, H.; Basset-Merle, A.; Chanez, P. Air trapping in mild and moderate asthma: Effect of inhaled corticosteroids. J. Allergy Clin. Immunol. 2007, 119, 583–590.
  73. Schniering, J.; Gabrys, H.; Brunner, M.; Distler, O.; Guckenberger, M.; Bogowicz, M.; Vuong, D.; Karava, K.; Müller, C.; Frauenfelder, T.; et al. Computed-tomography-based radiomics features for staging of interstitial lung disease—Transferability from experimental to human lung fibrosis—A proof-of-concept study. Eur. Respir. Soc. 2019, 54, PA4806. Available online: (accessed on 23 October 2020).
  74. Stefano, A.; Gioè, M.; Russo, G.; Palmucci, S.; Torrisi, S.E.; Bignardi, S.; Basile, A.; Comelli, A.; Benfante, V.; Sambataro, G.; et al. Performance of Radiomics Features in the Quantification of Idiopathic Pulmonary Fibrosis from HRCT. Diagnostics 2020, 10, 306.
  75. Martini, K.; Baessler, B.; Bogowicz, M.; Blüthgen, C.; Mannil, M.; Tanadini-Lang, S.; Schniering, J.; Maurer, B.; Frauenfelder, T. Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: Proof of concept. Eur. Radiol. 2021, 31, 1987–1998.
  76. Ungprasert, P.; Wilton, K.M.; Ernste, F.C.; Kalra, S.; Crowson, C.S.; Rajagopalan, S.; Bartholmai, B.J. Novel Assessment of Interstitial Lung Disease Using the “Computer-Aided Lung Informatics for Pathology Evaluation and Rating” (CALIPER) Software System in Idiopathic Inflammatory Myopathies. Lung 2017, 195, 545–552.
  77. Kim, H.J.; Brown, M.S.; Chong, D.; Gjertson, D.W.; Lu, P.; Kim, H.J.; Coy, H.; Goldin, J.G. Comparison of the Quantitative CT Imaging Biomarkers of Idiopathic Pulmonary Fibrosis at Baseline and Early Change with an Interval of 7 Months. Acad. Radiol. 2015, 22, 70–80.
  78. De Giacomi, F.; Raghunath, S.; Karwoski, R.; Bartholmai, B.J.; Moua, T. Short-term Automated Quantification of Radiologic Changes in the Characterization of Idiopathic Pulmonary Fibrosis Versus Nonspecific Interstitial Pneumonia and Prediction of Long-term Survival. J. Thorac. Imaging 2018, 33, 124–131.
  79. Lee, C.U.; Chong, S.; Choi, H.W.; Choi, J.C. Quantitative image analysis using chest computed tomography in the evaluation of lymph node involvement in pulmonary sarcoidosis and tuberculosis. PLoS ONE 2018, 13, e0207959.
  80. Best, A.C.; Meng, J.; Lynch, A.M.; Bozic, C.M.; Miller, D.; Grunwald, G.K.; Lynch, D.A. Idiopathic pulmonary fibrosis: Physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008, 246, 935–940.
  81. Maldonado, F.; Moua, T.; Rajagopalan, S.; Karwoski, R.A.; Raghunath, S.; Decker, P.A.; Hartman, T.E.; Bartholmai, B.J.; Robb, R.A.; Ryu, J.H. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur. Respir. J. 2014, 43, 204–212.
  82. Jacob, J.; Bartholmai, B.J.; Rajagopalan, S.; Kokosi, M.; Nair, A.; Karwoski, R.; Walsh, S.L.F.; Wells, A.U.; Hansell, D.M. Mortality prediction in idiopathic pulmonary fibrosis: Evaluation of computer-based CT analysis with conventional severity measures. Eur. Respir. J. 2017, 49, 1601011.
  83. Kim, H.J.; Brown, M.S.; Elashoff, R.; Li, G.; Gjertson, D.W.; Lynch, D.A.; Strollo, D.C.; Kleerup, E.; Chong, D.; Shah, S.K.; et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur. Radiol. 2011, 21, 2455–2465.
  84. Walsh, S.L.F.; Calandriello, L.; Silva, M.; Sverzellati, N. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: A case-cohort study. Lancet Respir. Med. 2018, 6, 837–845.
  85. Kiely, D.; Lawrie, A.; Doyle, O.; Salvatelli, V.; Daniels, F.; Drage, E.; Jenner, H.; Rigg, J.; Schmitt, C.; Samyshkin, Y.; et al. Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension. Eur. Respir. Soc. 2018, 52, PA3082. Available online: (accessed on 23 March 2021).
  86. Avendi, M.R.; Kheradvar, A.; Jafarkhani, H. Automatic segmentation of the right ventricle from cardiac MRI using a learning-based approach: Automatic Segmentation Using a Learning-Based Approach. Magn. Reson. Med. 2017, 78, 2439–2448.
  87. Avendi, M.R.; Kheradvar, A.; Jafarkhani, H. A combined deep-learning and deformable-model approach to fully automatic segmentation of the left ventricle in cardiac MRI. Med. Image Anal. 2016, 30, 108–119.
  88. Kiely, D.G.; Levin, D.L.; Hassoun, P.M.; Ivy, D.; Jone, P.-N.; Bwika, J.; Kawut, S.M.; Lordan, J.; Lungu, A.; Mazurek, J.A.; et al. Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm. Circ. 2019, 9, 204589401984199.
  89. Lungu, A.; Swift, A.; Capener, D.; Kiely, D.; Hose, R.; Wild, J. Diagnosis of pulmonary hypertension from MR image based computational models of pulmonary vascular haemodynamics and decision tree analysis. Eur. Respir. Soc. 2015, 46, PA2109. Available online: (accessed on 6 December 2020).
  90. Yang, M.; Ren, Y.; She, Y.; Xie, D.; Sun, X.; Shi, J.; Zhao, G.; Chen, C. Imaging phenotype using radiomics to predict dry pleural dissemination in non-small cell lung cancer. Ann. Transl. Med. 2019, 7, 259.
Subjects: Pathology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 323
Revisions: 2 times (View History)
Update Date: 12 Jul 2021
Video Production Service